Cognitive Behavioral Therapy for Painful Diabetic Neuropathy

NCT ID: NCT00830011

Last Updated: 2011-07-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-09-30

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to evaluate the usefulness of cognitive behavioral therapy (CBT) for the management of painful diabetic neuropathy. Participants will be randomly assigned to one of two treatment conditions: CBT plus standard medical care or standard medical care alone. CBT will be offered in ten, ninety-minute group sessions and will be provided by a psychologist with experience in the management of both diabetes and chronic pain. CBT will involve teaching and encouraging practice of adaptive pain coping skills such as relaxation skills, activity pacing, and positive self-statements, among others. This study will allow us to determine which treatment is superior in terms of improvements in pain management, functioning and overall quality of life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Research Design: A randomized mixed factorial controlled design will be employed in which CBT plus standard pharmaceutical care (CBT/SC) is compared to a standard pharmaceutical care (SC) treatment condition. Participants will be randomized in equal numbers to the two conditions. Repeated assessments of key outcome domains will occur at pretreatment/baseline and at 12, 24 and 36 weeks following baseline.

Methodology: Study participants will be evaluated pre-treatment (baseline), 12 weeks post-baseline (post-treatment) and at 24 and 36 weeks post-baseline (follow-up). Baseline assessment will include a neurological examination with a nerve conduction study to confirm the diagnosis of diabetic neuropathy. The primary outcome measure will be pain intensity. Secondary outcome measures will be pain quality, pain-related disability, physical and emotional functioning. Measures of treatment feasibility will also be examined. Participants receiving CBT will attend 10 weekly, group treatment sessions of 90 minutes. A target sample size of approximately 120 participants will be recruited.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Neuropathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

standard care

Medical care including medication for neuropathic pain

Group Type ACTIVE_COMPARATOR

standard medical care

Intervention Type OTHER

any care recommended by physician for treatment of diabetic neuropathy including medication.

CBT

Group Type ACTIVE_COMPARATOR

cognitive behavioral therapy

Intervention Type BEHAVIORAL

Ten sessions of manualized CBT delivered by a PhD level psychologist

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cognitive behavioral therapy

Ten sessions of manualized CBT delivered by a PhD level psychologist

Intervention Type BEHAVIORAL

standard medical care

any care recommended by physician for treatment of diabetic neuropathy including medication.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* type 2 diabetes mellitus
* daily lower extremity pain or discomfort (burning, tingling or other parasthesias) for at least 3 months
* documented trial of at least one medication for neuropathic pain
* pain of at least 4 on a 0-10 numeric rating scale

Exclusion Criteria

* acute medical condition, substance abuse, or psychiatric condition that would impair ability to participate
* dementia (MMSE score of 23 or lower)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Donaghue Medical Research Foundation

OTHER

Sponsor Role collaborator

VA Connecticut Healthcare System

FED

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

VA Connecticut Healthcare System

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Robert Kerns, PhD

Role: PRINCIPAL_INVESTIGATOR

VA Connecticut Healthcare System

References

Explore related publications, articles, or registry entries linked to this study.

Higgins DM, Heapy AA, Buta E, LaChappelle KM, Serowik KL, Czlapinski R, Kerns RD. A randomized controlled trial of cognitive behavioral therapy compared with diabetes education for diabetic peripheral neuropathic pain. J Health Psychol. 2022 Mar;27(3):649-662. doi: 10.1177/1359105320962262. Epub 2020 Oct 19.

Reference Type DERIVED
PMID: 33070667 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.diabetes.org

American Diabetes Association

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DF03-35

Identifier Type: -

Identifier Source: secondary_id

RK0029

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Neuropsychiatric Factors
NCT03323281 UNKNOWN
Driving with Neuropathy
NCT06739135 RECRUITING NA